Blincyto Receives Expanded Indication to Include Patients with Ph+ B-Cell Precursor ALL

Web Exclusives - FDA Approvals, News & Updates

On July 11, 2017, the FDA approved an expanded indication for blinatumomab (Blincyto; Amgen) to include the treatment of patients with Philadelphia chromosome (Ph)-positive (Ph+), relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

This current regular FDA approval also provides confirmation of the 2014 accelerated approval granted to blinatumomab for the treatment of patients with Ph-negative relapsed or refractory B-cell precursor ALL. It also expands the indication to include all patients with relapsed or refractory B-cell precursor ALL, regardless of their Ph chromosome status.

The study that confirmed the initial approval was based on TOWER, a randomized clinical trial that compared blinatumomab and standard-of-care chemotherapy in 405 patients with relapsed or refractory B-cell precursor ALL. Results showed significant improvement in overall survival (OS) with blinatumomab versus chemotherapy (hazard ratio, 0.71; P = .012); the estimated median OS was 7.7 months versus 4.0 months, respectively.

The expanded indication to patients with Ph+ disease was based on ALCANTARA, a single-arm multicenter study of 45 patients with Ph+ relapsed or refractory with relapsed or refractory B-cell precursor ALL. Overall, 36% of patients reached complete remission with blinatumomab, with a median remission duration of 6.7 months.

The 2 studies did not report any new major adverse events.

Related Items
February 8, 2019 - FDA Approvals, News & Updates
Web Exclusives published on February 1, 2019 in FDA Approvals, News & Updates, In the News, In the News
February 1, 2019 - FDA Approvals, News & Updates
Web Exclusives published on February 1, 2019 in FDA Approvals, News & Updates, In the News, In the News
Government Shutdown Impacts FDA Drug Approvals
Web Exclusives published on January 14, 2019 in FDA Approvals, News & Updates, In the News
FDA Approvals, News & Updates - August 2018
August 2018 Vol 11, Special Issue published on August 20, 2018 in FDA Approvals, News & Updates
Oncology Drugs Approved by the FDA in Early 2018
June 2018 Vol 11, No 4 published on June 25, 2018 in FDA Approvals, News & Updates
Last modified: August 10, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME